^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

FP14.15 - Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies.

Published date:
01/12/2021
Excerpt:
Neratinib, as monotherapy, has limited activity in HER2-mutated NSCLC. Neratinib combined with either an mTOR inhibitor (temsirolimus) or anti-HER2 antibody (trastuzumab) produced numerically greater efficacy including durable responses in a subset of pre-treated patients.